Products
& platforms
Adocia mission is to develop innovative formulations of approved peptides and novel cell therapy approaches for the treatment of diabetes and obesity.
- Home
- >
- Products and platforms
- >
- Pipeline
Pipeline
Over the years, Adocia has built a diversified pipeline of specialty products for the treatment of diabetes and obesity.
The products development stage ranges from preclinical proof of concept to Phase 3 clinical trials.
BioChaperone® GLP-1 Amylin
Platform: BioChaperone®
BioChaperone®
Lispro
Phase 3 in USA / Europe ready to start upon partnership signature
Partnering: Licensed to Tonghua Dongbao for China and other Asian territories. Available for other territories.
Product description: BioChaperone® Lispro (BC Lispro) is a novel ultra-rapid prandial insulin formulation containing insulin lispro and Adocia proprietary technology platform BioChaperone®. The BioChaperone® excipient ensures a faster absorption of insulin post injection and enables a more effective management of blood glucose levels.
Platform: BioChaperone®
Long acting + Rapid acting
BioChaperone® Combo
Partnering: Available for partnering.
Product description: BioChaperone® Combo(BC Combo) is a fixed combination of two gold standard insulins: long-acting insulin glargine and rapid-acting insulin lispro. BC Combo is a safer alternative to premixed insulin for treatment intensification in people with type 2 diabetes with a reduction of the level of postprandial hyperglycemia and the risk of late hypoglycemia.
Platform: BioChaperone®
AdoShell®
Islets
Partnering: Available for partnering
Product description: AdoShell® Islets is a hydrogel-based implant containing islets of Langerhans for cell therapy against type 1 diabetes.
It improves significantly the current transplantation protocols by removing the immunosuppressive treatment and making the implanted islets retrievable.
Platform: AdoShell®
M1Pram
Partnering: Sanofi
Product description: M1Pram is a ready-to-use co-formulation of pramlintide (an amylin analog) and M1 (a mealtime insulin analog).
Adocia has developed M1Pram to enable patients affected by both diabetes and overweight or obesity to address weight management and glycemic control as co-primary targets of care.
BioChaperone® LisPram
Partnering: Sanofi
Product description: BioChaperone® LisPram is a ready-to-use co-formulation of pramlintide (an amylin analog) and lispro (gold standard mealtime insulin analog). It is designed to be administered via insulin pump, in which it differs from M1Pram. BioChaperone® LisPram aims to maintain a good glycemic control, while triggering significant weight loss.
Platform: BioChaperone®
AdOral®
Sema
Partnering: Available for partnering
Product description: AdOral® Sema is an orally administered glucagon-like peptide 1 (GLP1) receptor agonist: semaglutide. Adocia has applied its AdOral® technology to switch the active molecule from an injectable to an oral form.
Platform: AdOral®
AdoGel® Sema
Partnering: Available for partnering
Product description: AdoGel® Sema is a ready-to-use injectable hydrogel for long-acting drug delivery of semaglutide. Preclinical proof of concept is underway. The key differentiating attribute lies in its controlled release mechanism allowed by the AdoGel ® platform, characterized by nearly zero-order kinetics with no initial burst, ensuring steady release of the semaglutide into the bloodstream.
Platform: AdoGel®